Press Releases

INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has received regulatory authorization from Brazil's ANVISA (Agência Nacional de Vigilância Sanitária), the national health regulatory agency of Brazil, to initiate the global Phase 3 segment of its Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Effic

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has received two new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA). KEYTRUDA is approved for the treatment of patients with PD-L1-positive, hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-negative, inoperable or recurrent breast cancer, based on the results of the Phase 3 KEYNOTE-355 trial. Additionally, KEYTRUDA a

CB Therapeutics is a leading biosynthesis company focused on the research and development of environmentally-friendly products to improve mental health, increase healthspan, and promote longevity. CB Therapeutics is happy to announce that it has been awarded two more patents for the novel methods of production of high value molecules using cutting-edge biosynthesis technologies. These patents (11,041,002B1 and 10,988,785B1) cover inventions on cellular agriculture breakthroughs for

BioAesthetics Corporation today announced that it has received a Small Business Technology Transfer (STTR) Phase I grant through the National Institute of General Medical Sciences (NIGMS) to further develop its platform technology of enhanced biologically derived grafts — capable of sustained drug delivery — to improve outcomes for third degree burn survivors in collaboration with the University of Miami Miller School of Medicine. These grants are awarded with the objective of tra

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that it has reacquired the exclusive rights to develop and commercialize its all-oral combination product candidate in the People's Republic of China previously licensed to Shenzhen Salubris Pharmaceuticals Co., Ltd. (Salubris).  Pursuant to the mutual termination agreement between Viracta and Salubris, all development and commercialization rights under the license have b

Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that China's National Medical Products Administration has approved a Phase II study of selinexor (XPOVIO®) for the treatment of patients with myelofibrosis (MF). MF is a clonal bone narrow neoplasm which can emerge either as primary MF (PMF), p

Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by Merck & Co., Inc. to be in the specialty pharmacy network for WELIREG (belzutifan), a hypoxia-inducible factor inhibitor indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

Scioto Biosciences, Inc. announced the beginning of their Phase Ib clinical trial for their lead investigational product SB-121 for the treatment of Autistic Disorder (AD). The first patient was randomized and started dosing in mid-August. Scioto is an innovation-driven biotechnology company focused on developing a novel microbiome platform called Activated Bacterial Therapeutics (ABT). SB-121 is the first ever ABT to be tested in the clinic. The Phase Ib trial is being conducted in

Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics, a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI. Leveraging the revolutionary Cerebras CS-2 system – powered by the world’s fastest AI processor – Peptilogics will be able to push the boundaries of

Castor, a leading provider of clinical trial technology to democratize clinical research, announced that it is powering the next generation of clinical trials with more than 30 digital therapeutics (DTx) studies ongoing. A new class of therapeutics is rapidly advancing medicine: digital therapeutics or “DTx”. These digital treatments have disease-modifying properties that are effective for a wide range of debilitating and deadly diseases. Castor is supporting this fast-g